Neumora Therapeutics, Inc. Common Stock (NMRA)
Automate Your Wheel Strategy on NMRA
With Tiblio's Option Bot, you can configure your own wheel strategy including NMRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NMRA
- Rev/Share 0.0
- Book/Share 1.4144
- PB 0.5585
- Debt/Equity 0.0041
- CurrentRatio 8.9792
- ROIC -1.1977
- MktCap 127780857.0
- FreeCF/Share -1.2304
- PFCF -0.6432
- PE -0.4943
- Debt/Assets 0.0037
- DivYield 0
- ROE -0.8479
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NMRA | BofA Securities | Buy | Underperform | -- | $1 | April 2, 2025 |
| Downgrade | NMRA | William Blair | Outperform | Market Perform | -- | -- | March 10, 2025 |
| Downgrade | NMRA | Guggenheim | Buy | Neutral | -- | -- | March 7, 2025 |
| Downgrade | NMRA | Stifel | Buy | Hold | $6 | $2 | March 7, 2025 |
| Downgrade | NMRA | RBC Capital Mkts | Outperform | Sector Perform | $29 | $4 | Jan. 2, 2025 |
| Initiation | NMRA | H.C. Wainwright | -- | Buy | -- | $30 | Oct. 1, 2024 |
News
Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132585&wire=1 or contact Joseph E. Levi, Esq.
Read More
Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses
Published: February 26, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 26, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering ("IPO") on September 15, 2023. Neumora is a clinical-stage biopharmaceutical company.
Read More
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NMRA
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132558&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ:NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Neumora common stock you may be entitled to compensation without payment of any out of pocket fees or …
Read More
Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRA
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Read More
Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132488&wire=1 or contact Joseph E. Levi, Esq.
Read More
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132293&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
Shareholders that lost money on Neumora Therapeutics, Inc. (NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132249&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora's September 2023 initial public offering (the “IPO”), of the important April 7, 2025 lead plaintiff deadline.
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NMRA
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132117&wire=1 or contact Joseph E. Levi, Esq.
Read More
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132113&wire=1 or contact Joseph E. Levi, Esq.
Read More
A Securities Fraud Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the firm before April 7, 2025.
Read More
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=131941&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=131921&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora's September 2023 initial public offering (the “IPO”), of the important April 7, 2025 lead plaintiff deadline.
Read More
Class Action Reminder for NMRA Investors: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Securities Fraud Class Action Lawsuit
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
RADNOR, Pa. , Feb. 24, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or around September 15, 2023.
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NMRA
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=131887&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NMRA
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc.(NASDAQ:NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Neumora common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=131835&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"). If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Neumora Therapeutics, Inc.
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the firm before April 7, 2025.
Read More
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA
Published: February 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=131667&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Published: February 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (the “IPO”) held on September 15, 2023, have until Monday, April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit. Captioned Chang v. Neumora Therapeutics, Inc., No. 25-cv-01072 (S.D.N.Y.), the Neumora class action lawsuit charges Neumora and certain of Neumora's top executives and directors, and certain underwriters of the IPO, with violations of …
Read More
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=131652&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Neumora Therapeutics, Inc. Common Stock (NMRA)
- IPO Date 2023-09-15
- Website https://www.neumoratx.com
- Industry Biotechnology
- CEO Dr. Daljit Singh Aurora Pharm.D.
- Employees 110